¹ã¶«»áÈ«Õ¾¹ã¶«»áÔÚÏߵǼ¿Æѧ¹ËÎÊίԱ»á£¨SAB£©³ÉÔ±£¬ÃÀ¹úÓ¡µÚ°²ÄÉ´óѧXiongbin Lu½ÌÊÚ¿ÎÌâ×éÔÚNBEÔÓÖ¾ÉÏ·¢±íÖØÒªÎÄÕÂ

½üÈÕ£¬¹ã¶«»áÈ«Õ¾¹ã¶«»áÔÚÏߵǼ¿Æѧ¹ËÎÊίԱ»á³ÉÔ±£¬ÃÀ¹úÓ¡µÚ°²ÄÉ´óѧXiongbin   Lu½ÌÊÚ¿ÎÌâ×éÔÚNature Biomedical Engineering ÔÓÖ¾ÉÏ·¢±íÁËÎÄÕÂAn organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity£¬±¨µÀÁËÒ»ÖÖ»ùÓÚСÊó»ò°©Ö¢»¼ÕßÀ´Ô´µÄÈéÏÙÖ×ÁöÀàÆ÷¹Ù(Tumor organoids) ÁªºÏÖ×ÁöÌØÒìÐÔTϸ°û¹¦ÄÜÏ໥×÷ÓõĸßͨÁ¿É¸Ñ¡·½·¨£¬ÓÃÒÔɸѡ³öÄܹ»´Ù½ø¿¹Ô­³ÊµÝºÍÔöÇ¿Tϸ°û½éµ¼µÄϸ°û¶¾ÐÔ±í¹ÛÒÅ´«ÒÖÖƼÁ¡£

ÔÚÈéÏÙ°©ÖУ¬ÒÅ´«ÒìÖÊÐÔ¡¢È±·¦¿ÉÓõİеãºÍÃâÒßÌӱܶ¼Êǵ¼ÖÂÃâÒß¼ì²éµã×è¶ÏÖÎÁÆÁÙ´²·´Ó¦ÂÊÓÐÏÞµÄÔ­Òò¡£ÃâÒß·ÖÎö¡¢×ۺ϶à×éѧ·ÖÎöºÍÖ×Áö΢»·¾³Ñо¿½ÒʾÁËÈéÏÙ°©ÃâÒßÌӱܻúÖÆÓëÆÕ±é´æÔÚµÄÖ×Áö¿¹Ô­µÄÃâÒßʶ±ðÒÖÖÆ´æÔÚÓÐÏÔÖø¹Øϵ¡¾1¡¿¡£ÔÚÖ×Áö²úÉúºÍ½øÕ¹¹ý³ÌÖУ¬Ò»Ð©»ùÒòµÄת¼ÒÖÖÆ£¬ÈçÓ뿹ԭ´¦ÀíºÍ³ÊµÝÏà¹ØµÄ»ùÒò¡¢ÃâÒß¼ì²éµã»ùÒò¡¢Ç÷»¯Òò×ÓºÍÆäËûÃâÒßÏà¹Ø»ùÒò£¬½µµÍÁËÖ×Áöϸ°ûÓëÖ×Áö½þÈóÁÜ°Íϸ°ûµÄÏ໥×÷Ó㬴ӶøʹÖ×Áöϸ°ûÌÓÍÑÃâÒß¹¥»÷¡£µ÷¿Ø±í¹ÛÒÅ´«µÄÒ©ÎÈçDNA¼×»ùתÒÆøºÍ×éµ°°×È¥ÒÒõ£»¯Ã¸ÒÖÖƼÁ£¬±»ÈÏΪ¾ßÓÐͨ¹ýÖرà³ÌÖ×Áöϸ°û»ùÒòת¼£¬´Ó¶ø¾ßÓÐÄæתÃâÒßÒÖÖƵŦÄÜ¡¾2¡¿¡£Ä¿Ç°¶Ô°©Ï¸°û±í¹ÛÒÅ´«Ñ§µÄÑо¿½øÕ¹£¬½«´Ù½øÎÒÃǶÔÈËÀà°©Ö¢ÃâÒßµÖ¿¹µÄÈÏʶ£¬²¢ÎªÊ¹Óñí¹ÛÒÅ´«ºÍÃâÒßÖÎÁÆÁªºÏÒ©Îï×÷Ϊ¿¹°©ÖÎÁƽ¨Á¢¼áʵµÄÁÙ´²Ç°Ñо¿¿ª·¢»ù´¡¡¾3¡¿¡£¾¡¹ÜÈéÏÙ°©ÃâÒßÖÎÁÆÊÇÒ»¸ö·¢Õ¹Ñ¸ËÙµÄÁìÓò£¬µ«ÓÃÓÚ¸ßͨÁ¿Ò©Îï·¢ÏÖºÍÑéÖ¤µÄ¼¼Êõ·½·¨ºÍ¶¯ÎïÄ£ÐÍÖͺóÓÚÆä·¢Õ¹¡£ÓÃÓÚÆÀ¹ÀÖ×ÁöÃâÒßʶ±ðµÄÖ×ÁöÆ÷¹ÙÄ£ÐͳÉΪÃâÒßÖÎÁÆ»òÁªºÏÖÎÁÆÒ©ÎïɸѡµÄ×îÓÐÁ¦¹¤¾ßÖ®Ò»¡£

¾Ý±¨µÀ£¬ËûÃǽ¨Á¢µÄÒ©Îïɸѡ»úÖÆÈçͼ1¡£Ê×ÏȽ«Äܹ»±í´ïOVA¶ÌëĵÄСÊóÈéÏÙ°©Ï¸°ûԭλÒÆÖ²µ½ÃâÒßÕý³£µÄC57BL/6СÊó£¬ÒÔ²úÉúÈéÏÙÖ×Áö¡£ÊÕ¼¯Ö×Áö²¢½«Æä·ÖÀë³Éµ¥¸öϸ°û½øÐÐ2DÅàÑø£¬Ö»ÊÕ¼¯Ìù±Úϸ°ûÒÔÉú³ÉÖ×ÁöÀàÆ÷¹Ù¡£½«Ò»¶¨Ö±¾¶µÄÖ×ÁöÀàÆ÷¹ÙÔÚÎÞ»ùÖÊÅàÑø»ùÖиøÓèÒ©ÎïÖÎÁÆ48Сʱ¡£ÓëOVA-specific CD8   Tϸ°û¹²Í¬ÅàÑø£¬½øÒ»²½É¸Ñ¡³öÄܹ»ÓÃÒÔɸѡ³öÄܹ»´Ù½ø¿¹Ô­³ÊµÝºÍÔöÇ¿Tϸ°û½éµ¼µÄϸ°û¶¾ÐÔµÄÒ©Îï¡£±¾Ñо¿¶ÔÓÃÓÚÒ©ÎïɸѡµÄÈéÏÙÖ×ÁöÀàÆ÷¹ÙµÄϸ°û×é·Ö£¬´óС£¬Ö×Áö·¢Éú£¨tumorigenesis£©ºÍÖ×ÁöȱÑõÌõ¼þ½øÐÐÁËÑо¿Óë·ÖÎö£¬Ê¹Ö®ÓëСÊóÌåÄÚÖ×Áö΢»·¾³Ìù½ü¡£

      ×÷ÕßÏÂÒ»²½ÀûÓÃÈýÖÖ²»Í¬µÄɸѡ·½·¨£¨ÈéÏÙÖ×ÁöÀàÆ÷¹Ù-Tϸ°ûÄ£ÐÍ£¬2DÈéÏÙÖ×Áöϸ°û-T ϸ°ûÄ£ÐÍ£¬Ö×Áöϸ°û¿¹Ô­³ÊµÝ±í´ïɸѡģÐÍ£©¶ÔºòÑ¡Ò©Îï½øÐÐɸÑ¡£¬²¢¶ÔËüÃǵÄÓÅÁÓ½øÐÐÁ˱ȽÏ¡£×÷Õß·¢ÏÖ£¬¾­É¸Ñ¡¼ø¶¨µÄ±í¹ÛÒÅ´«ÒÖÖƼÁGSK-LSD1¡¢CUDC-101ºÍBML-210ÔÚСÊóԭλÈéÏÙÖ×ÁöÖÐÏÔʾ³ö¿¹Ö×Áö»îÐÔ£¬²¢ÔÚ¾ßÓÐ×ÔÌåÖ×Áö½þÈóTϸ°ûµÄÈËÀ໼ÕßÔ´ÐÔÖ×ÁöÆ÷¹Ù (PDOs) Öеõ½½øÒ»²½ÑéÖ¤¡£½øÒ»²½Ñо¿½á¹ûÏÔʾÁËÕâЩҩÎïÃ÷ÏÔµØÉϵ÷ÁËÈéÏÙÖ×Áöϸ°ûÖ÷Òª×éÖ¯ÏàÈÝÐÔ¸´ºÏÌåIÀà½éµ¼µÄ¿¹Ô­µÝ³Ê¡£ÁíÍ⣬ʹÓÃBML-210ÖÎÁƺó£¬ÈéÏÙÖ×Áö¶ÔÃâÒß¼ì²éÒÖÖƼÁPD-1 µ¥¿¹µÄÖÎÁÆÃô¸Ð¶ÈÏÔÖøÔö¸ß ¡£Õâ¸öÖ×ÁöÀàÆ÷¹Ù-Tϸ°ûɸѡƽ̨½¨Á¢ÁËÖ×Áöϸ°ûɱÉË»îÐԵıê×¼»¯²âÁ¿£¬²¢¿ÉÓÃÓÚɸѡһϵÁа©Ö¢µÄºòÑ¡ÃâÒßÁÆ·¨¡£

ÃÀ¹úÓ¡µÚ°²ÄÉ´óѧÑо¿ÖúÀí½ÌÊÚÖÜ׿Áú²©Ê¿Îª±¾Ñо¿µÄµÚÒ»×÷Õß¡£Ëû½ü¼¸ÄêµÄÑо¿·½ÏòÖ÷ÒªÊÇ´ÓÊÂ3DÖ×ÁöÀàÆ÷¹ÙÄ£Ð͵Ŀª·¢ÓëÔËÓ㬰©Ö¢ÃâÒßÒ©ÎïµÄÖÎÁÆ»úÖƵÈÑо¿¡£ÃÀ¹úÓ¡µÚ°²ÄÉ´óѧXiongbin   Lu½ÌÊÚÓëXinna Zhang ½ÌÊÚΪ¹²Í¬Í¨Ñ¶×÷Õß¡£Xiongbin Lu ½ÌÊÚΪӡµÚ°²ÄÉ´óѧSimon×ۺϰ©Ö¢ÖÐÐÄExperimental and Developmental Therapeutics ProgramµÄ¹²Í¬¸ºÔðÈË£¬¶àÄêÀ´´ÓÊ°©Ö¢¾«×¼ÖÎÁƺÍÃâÒßÖÎÁƵȷ½ÃæµÄÑо¿¡£Xiongbin Lu½ÌÊÚ´øÁìµÄ¿ÎÌâ×é½üÄêÀ´ÔÚ°©Ö¢ÖÎÁÆ·½ÃæµÄ¶àÏîÑо¿³É¹û·Ö±ðÔÚNature, Nature Nanotechnology, Science Translational Medicine, Cancer Cell ºÍJournal of Clinical InvestigationµÈ¶à¸öÔÓÖ¾ÉÏ·¢±í¡£

1. Zacharakis, N. et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 24, 724-730 (2018).

2. Villanueva, L., Alvarez-Errico, D. & Esteller, M. The Contribution of Epigenetics to Cancer Immunotherapy. Trends Immunol 41, 676-691 (2020).

3. Dravis, C. et al. Epigenetic and Transcriptomic Profiling of Mammary Gland Development and Tumor Models Disclose Regulators of Cell State Plasticity. Cancer Cell 34, 466-482 e466 (2018).